Drug
Screening Platform
Screening Platform is a pharmaceutical drug with 5 clinical trials. Currently 2 active trials ongoing. Historical success rate of 50.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
50.0%
Based on 1 completed trials
Completion Rate
50%(1/2)
Active Trials
2(40%)
Results Posted
100%(1 trials)
Terminated
1(20%)
Phase Distribution
Ph phase_2
3
60%
Phase Distribution
0
Early Stage
3
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 2Efficacy & side effects
3(100.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
50.0%
1 of 2 finished
Non-Completion Rate
50.0%
1 ended early
Currently Active
2
trials recruiting
Total Trials
5
all time
Status Distribution
Active(3)
Completed(1)
Terminated(1)
Detailed Status
Terminated1
Active, not recruiting1
Not yet recruiting1
Completed1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
2
Success Rate
50.0%
Most Advanced
Phase 2
Trials by Phase
Phase 23 (100.0%)
Trials by Status
terminated120%
active_not_recruiting120%
not_yet_recruiting120%
completed120%
recruiting120%
Recent Activity
2 active trials
Showing 5 of 5
completedphase_2
Screening Study for Participants With Malignant Tumors
NCT05419375
recruitingphase_2
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
NCT03851445
active_not_recruiting
DRG Mutations in Prostate Cancer: a Guiding Light for Enhanced Screening and Personalised Therapy
NCT07265414
not_yet_recruiting
Influence of Acute Daily Workload Changes on Low-frequency Fatigue Morning Scores
NCT06704854
terminatedphase_2
Screening Protocol for Preliminary Eligibility Determination for Adoptive Cell Therapy Trials
NCT05100316
Clinical Trials (5)
Showing 5 of 5 trials
NCT05419375Phase 2
Screening Study for Participants With Malignant Tumors
NCT03851445Phase 2
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
NCT07265414
DRG Mutations in Prostate Cancer: a Guiding Light for Enhanced Screening and Personalised Therapy
NCT06704854
Influence of Acute Daily Workload Changes on Low-frequency Fatigue Morning Scores
NCT05100316Phase 2
Screening Protocol for Preliminary Eligibility Determination for Adoptive Cell Therapy Trials
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5